Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Verona Pharma Limited is navigating 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This workload is distributed across 1 distinct examiner and 1 distinct art unit, reflecting a narrow point of contact with the USPTO for the company's pending matters. Such a focused profile allows for a highly targeted prosecution strategy without the need to manage diverse examiner behaviors.
The busiest examiner, NGUYEN, NGOC-ANH THI, is handling 1 pending office action. Prosecution success for this portfolio currently hinges on the specific examination style of this individual within the pharmaceutical sector. Practitioners should analyze the examiner's previous actions to anticipate potential hurdles in this 1 pending office action.
The presence of only 1 distinct art unit suggests that the company's current pharmaceutical innovations are being evaluated under a consistent set of internal USPTO policies. Because the 1 pending office action is the only active matter, the applicant can focus entirely on the technical requirements of this specific art unit to ensure the continued growth of the Biotechnology & Pharmaceuticals portfolio. This 1 distinct examiner represents the sole gateway to securing the company's latest intellectual property assets.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NGUYEN, NGOC-ANH THI | 1 | 28.1% | +49.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17632891 | PHARMACEUTICAL COMPOSITION COMPRISING ENSIFENTRINE | NGUYEN, NGOC-ANH THI | 114d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17632891 | PHARMACEUTICAL COMPOSITION COMPRISING ENSIFENTRINE | NGUYEN, NGOC-ANH THI | 114d overdue |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17632891 | PHARMACEUTICAL COMPOSITION COMPRISING ENSIFENTRINE | NGUYEN, NGOC-ANH THI | 1615 | §103 | Final Rejection | 114d overdue | Pending | Feb 04, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial